Development of gelatin-methacryloyl composite carriers for bone morphogenetic Protein-2 delivery: A potential strategy for spinal fusion
Journal of Biomaterials Applications · 2024
DOI: 10.1177/08853282241258302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomaterials Applications, 2024. Verfasst von Tao Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Shaanxi, PR China. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 2, Spinal Fusion, Gelatin, Osteogenesis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Lanzhou University Cuiying Student Research and Cultivation Plan Project, Shaanxi Natural Science Basic Research Program.
Abstract (Originalsprache)
To reduce the risk of nonunion after spinal fusion surgery, the in situ transplantation of bone marrow mesenchymal stem cells (BMSCs) induced toward osteogenic differentiation by bone morphogenetic protein-2 (BMP2) has been proven effective. However, the current biological agents used for transplantation have limitations, such as a short half-life and low bioavailability. To address this, our study utilized a safe and effective gelatin-methacryloyl (GelMA) as a carrier for BMP2. In vitro, experiments were conducted to observe the ability of this composite vehicle to induce osteogenic differentiation of BMSCs. The results showed that the GelMA hydrogel, with its critical properties and controlled release performance of BMP2, exhibited a slow release of BMP2 over 30 days. Moreover, the GelMA hydrogel not only enhanced the proliferation activity of BMSCs but also significantly promoted their osteogenic differentiation ability, surpassing the BMP2 effects. To investigate the potential of the GelMA-BMP2 composite vehicle, a rabbit model was employed to explore its ability to induce in situ intervertebral fusion by BMSCs. Transplantation experiments in rabbits demonstrated the effective induction of intervertebral bone fusion by the GelMA-BMP2-BMSC composite vehicle. In conclusion, the GelMA-BMP2-BMSC composite vehicle shows promising prospects in preclinical translational therapy for spinal intervertebral fusion. It addresses the limitations of current biological agents and offers a controlled release of BMP2, enhancing the proliferation and osteogenic differentiation of BMSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Shaanxi, PR China.
- Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou, PR China.
ORCID-Profile: Zhengwei Xu
Förderung
- Lanzhou University Cuiying Student Research and Cultivation Plan Project
- Shaanxi Natural Science Basic Research Program
Zitieren
APA
Li, T., Zhang, X., Hu, Y., Gao, X., Yao, X., & Xu, Z. (2024). Development of gelatin-methacryloyl composite carriers for bone morphogenetic Protein-2 delivery: A potential strategy for spinal fusion. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282241258302
Vancouver
Li T, Zhang X, Hu Y, Gao X, Yao X, Xu Z. Development of gelatin-methacryloyl composite carriers for bone morphogenetic Protein-2 delivery: A potential strategy for spinal fusion. Journal of Biomaterials Applications. 2024. doi:10.1177/08853282241258302
BibTeX
@article{Li2024,
author = {Li, Tao and Zhang, Xiaobo and Hu, Yicun and Gao, Xidan and Yao, Xin and Xu, Zhengwei},
title = {Development of gelatin-methacryloyl composite carriers for bone morphogenetic Protein-2 delivery: A potential strategy for spinal fusion},
journal = {Journal of Biomaterials Applications},
year = {2024},
doi = {10.1177/08853282241258302}
}
EUVIMED